A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancer

A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancer - A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000147

Enrollment

Registered

2005-09-09

Start date

1997-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

second line chemotherapy for Non-Small cell lung cancer

Interventions

carboplatin/irinotecan combination docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-small cell lung cancer stage 3B or 4 life expectancy at least 3 month age 75 or younger PS 0-2 Adequate renal, liver and bone marrow function PaO2 65 torr or more

Exclusion criteria

Exclusion criteria: patient who received docetaxel or irinotecan

Design outcomes

Primary

Measure	Time frame
Primary endpoint:Response rate	—

Countries

Japan

Contacts

Public ContactKyoichi Okishio

National Hospital Organization Kinki-chuo chest medical center Respiratory Medicine

072-250-4034

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026